Dermatology Deal Benchmarks
Benchmark licensing terms for atopic dermatitis, psoriasis, vitiligo, alopecia areata, and other skin conditions. Dermatology deals benefit from large patient populations and growing biologic adoption. Benchmarks derived from 184 verified transactions.
184
Total Deals
$157M
Avg Upfront
5
Deal Types
100%
Terms Disclosed
Deal Structure Distribution
107
license
49
acquisition
17
collaboration
10
option
1
co development
Recent Deals with Disclosed Terms
| Parties | Type | Upfront | Total Value | Date |
|---|---|---|---|---|
Junshi Biosciences → Fosun Pharma roconkibart (JS005) | license | $30M | $186M | Jul 2026 |
Ascendant Health / Genesis Life Sciences → Cue Biopharma Ascendant-221 / CUE-221 | license | $15M | $692M | Apr 2026 |
Replay → Leo Pharma skin disease gene therapy | license | $50M | $50M | Apr 2026 |
Boehringer Ingelheim → AbbVie BI 655066 | license | $595M | — | Mar 2026 |
Teva Pharmaceuticals → Royalty Pharma TEV-53408 | license | $75M | $500M | Jan 2026 |
Royalty Pharma → Teva TEV-'408 | co development | $75M | $500M | Jan 2026 |
Hatchtech Pty Ltd → Pelthos Therapeutics Inc. Xeglyze | acquisition | $2M | $2M | Dec 2025 |
Acera Surgical → Solventum wound care products | acquisition | $725M | $850M | Nov 2025 |
Biofrontera Inc. / Ferrer Internacional S.A. → Pelthos Therapeutics, Inc. Xepi (ozenoxacin) Cream, 1% | acquisition | $4M | $11M | Nov 2025 |
Acrux Limited → Servacure Trading W.L.L. Dapsone 5%, Gel | license | $1M | $5M | Jul 2025 |
Benchmark Your Dermatology Deal
Get instant benchmarks for upfront payments, milestones, and royalties based on 184 verified dermatology transactions.
Dermatology Deal Benchmarking FAQ
How are atopic dermatitis deal valuations trending in 2026?
Atopic dermatitis remains the highest-value dermatology indication for deal-making, driven by the validated dupilumab franchise and competition among next-gen IL-13, IL-31, and OX40 approaches. Clinical-stage AD assets command upfronts of $50M-$200M+ with total deal values exceeding $1B for differentiated mechanisms.
What deal structures are common in dermatology licensing?
Dermatology deals frequently use geographic licensing structures, with licensors retaining North America and out-licensing ex-US rights. Co-promotion agreements are also common for launched products. Upfronts range $20M-$150M depending on indication breadth and stage, with royalties of 10-20% on net sales.
How do topical vs systemic dermatology deals compare?
Systemic dermatology deals (biologics, oral JAK inhibitors) command significantly higher valuations than topical deals, reflecting larger commercial potential. Topical deals typically feature lower upfronts ($5M-$30M) and royalties (5-12%), while systemic biologic deals for psoriasis and AD are benchmarked alongside immunology transactions.